Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease.
暂无分享,去创建一个
B. Storer | K. van Besien | Stephanie J. Lee | M. Flowers | D. Weisdorf | D. Couriel | R. Maziarz | Paul J. Martin | Vikas Gupta | M. Jagasia | C. Kitko | S. Rowley | P. Carpenter | P. Shaughnessy | Jack W. Hsu | J. Hsu | P. Martin
[1] J. Fay,et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. , 2009, Blood.
[2] E. Gatza,et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. , 2008, Blood.
[3] A. Balduzzi,et al. Extracorporeal Photochemotherapy Is Accompanied by Increasing Levels of Circulating CD4+CD25+GITR+Foxp3+CD62L+ Functional Regulatory T-Cells in Patients With Graft-Versus-Host Disease , 2007, Transplantation.
[4] L. Boon,et al. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+CD25+FoxP3+ T cells , 2007, Bone Marrow Transplantation.
[5] W. Murphy,et al. Immunobiology of allogeneic hematopoietic stem cell transplantation. , 2007, Annual review of immunology.
[6] R. Negrin,et al. Role of naturally arising regulatory T cells in hematopoietic cell transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[7] J. Ritz,et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. , 2006, Blood.
[8] M. Albert,et al. Assessing the potential role of photopheresis in hematopoietic stem cell transplant , 2006, Bone Marrow Transplantation.
[9] Christopher H Contag,et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. , 2006, Blood.
[10] P. Lachenbruch,et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[11] R. Storb,et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. , 2004, Blood.
[12] M. Flowers,et al. Chronic graft-versus-host disease. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[13] E. Cook,et al. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[14] J Crowley,et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.
[15] H. Deeg,et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. , 1988, Blood.
[16] K. Sullivan,et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. , 1981, Blood.
[17] R. Negrin,et al. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. , 2008, Blood.
[18] D. Peritt. Potential mechanisms of photopheresis in hematopoietic stem cell transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[19] M. MacMillan,et al. Chronic graft-versus-host disease: a prospective cohort study. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[20] K. Atkinson. Clinical bone marrow and blood stem cell transplantation , 2000 .